AML | Clinical

High-/Low-Dose Sabatolimab Exhibit Comparable Pharmacokinetics in MDS and AML

December 06, 2020

In patients with acute myeloid leukemia and myelodysplastic syndrome, treatment with sabatolimab administered at 200 mg every 2 weeks and 800 mg every 4 weeks demonstrated similar pharmacokinetic activity, according to findings from a dose-selection and dose-response analysis presented during the 2020 American Society of Hematology Annual Meeting.

HRQoL Maintained With Oral Azacitidine Along With OS and RFS Improvement in AML

December 06, 2020

Azacitidine administered orally to patients with acute myeloid leukemia demonstrated significant improvements in overall survival and relapse-free survival while sustaining the health-related quality of life compared with placebo.

Survival Outcome Influenced by Racial and Ethnic Related Socioeconomic Disparities in AML

December 05, 2020

Significant disparities between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia in the Chicago metropolitan area were seen with census tract socioeconomic status information.

Azacitidine/Venetoclax Represents New Gold Standard for Older Patients with Treatment-Naïve AML

November 13, 2020

In an interview with Targeted Oncology following the announcement of the FDA approval of azacitidine plus venetoclax in older patients with acute myeloid leukemia, Brian Jonas, MD, provided insight on the VILAE-A study results. He also gave expert advice on how to approach treating older patients with acute myeloid leukemia in every day practice.